Broadcom Corporation

Other

The Nielsen Comapny (us), LLC

Humanscale Corporation

Biokey, Inc.

Andrx Pharmaceuticals, Inc.

Magnifica Inc.

Synchroneuron, Inc.

Andrx Labs, LLC

Andrx Corporation, Inc.

Andrx Pharmaceutials, Inc.

David N Wong

Chih-Ming Chen

Kumar Nagaraja Rao

Joseph C Chou

San-Laung Chow

Jun Cao

Albert Ronald Perez

Stephen S Bell

Ross Velazquez

William Dai

Mimi Zhang

Cheng-Chung Shih

Tianjue Luo

Jennifer Haskell

Greg Allison

Aaron Klein

Robert Principe

Xi Chen

Damian Garcia

Peter Campbell Doe

Avinash Nangia

Boyong Li

Paul Donato

Peng Fei Yi

Barry S Fogel

Mainak Mazumdar

Robert Volek

Seema Varma Srivastava

Steve Bender

William D Kerns

Kei-Lai Fong

Paul R Baldwin

James A Lee

Edward Lin

Kate Wensie Wong

Spencer Wenyen Wong

Aaron Dely

Jenny Li-Ying Lin

John Guariglio

A monitor mounting system which includes a crossbar having at least one monitor mounting bracket positioned thereon. A support arm is configured to adjust the vertical height of the crossbar and a pivot assembly is positioned between the support arm and the crossbar, with the pivot assembly configured to allow limited pivot adjustment of the crossbar in order to level the crossbar to the horizontal position.

Rotating joint for crossbar leveling adjustment

Methods and apparatus to compensate impression data for misattribution and non-coverage are disclosed. An example method includes receiving a first request from a first type of computing device; sending a request for demographic information corresponding to requests received at a first internet domain from the first type of computing device; generating an aggregated audience distribution including a first audience distribution of a first household aggregated with a second audience distribution of a second household; normalizing the aggregated audience distribution to generate a misattribution correction matrix, the misattribution correction matrix including a probability that an impression of the media is attributable to a first demographic group when the database proprietor determines the impression corresponds to a person in a second demographic group; and compensating misattribution error in the impressions by re-assigning the impressions from the second demographic group to the first demographic group using the misattribution correction matrix.

Methods and apparatus to compensate for server-generated errors in database proprietor impression data due to misattribution and/or non-coverage

A computer docking station devised to save desktop space while also eliminating the presence of permanent cables that can clutter the work surface is disclosed. The computer docking station utilizes a split design, with a lower dock subassembly positioned beneath the work surface for housing the permanent cables necessary for the computer workstation to operate and an upper dock subassembly comprising one or more data ports positioned on top of the work surface. A monitor arm mount can be attached to, or integrated into, the upper dock subassembly, thereby alleviating the need for a separate monitor arm mount without negatively impacting the docking station's footprint.

Computer docking station

Methods and apparatus to compensate impression data for misattribution and non-coverage by a database proprietor are disclosed. An example method includes obtaining a count of media impressions occurring on a first type of computing device, a first portion of the media impressions corresponding to persons for whom demographic information is recognizable by a database proprietor and a second portion of the media impressions corresponding to persons for whom demographic information is unavailable to the database proprietor; and determining the demographic information for the second portion of the media impressions based on a first probability that media corresponding to the media impressions is accessed on the first type of computing device and based on a second probability that media is accessed on a second type of device.

Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Acamprosate formulations, methods of using the same, and combinations comprising the same

The present invention provides an injectable particle comprising dasatinib acetate and a hyaluronic acid. The hyaluronic acid may be acetylated or sulfated. The particle is for the use of cancer therapy. The injectable particle may further comprises an acid, wherein the acid is dispersed evenly in the matrix of the injectable particle.

Injectable particle

A disclosed example method to determine audience duplication in cross-media campaigns involves determining a first duplicated audience reach between a total television audience and an internet publisher audience for a demographic group. The total television audience is representative of audience members across a plurality of television networks, and the internet publisher audience is representative of audience members across one of a plurality of internet publishers. The example method involves determining a second duplicated audience reach between the total television audience and the internet publisher audience for a media campaign based on the first duplicated audience reach. The example method involves determining a third duplicated audience reach between a television network audience and the internet publisher audience for the media campaign based on the second duplicated audience reach. The television network audience is representative of audience members exposed to the media campaign via one of the plurality of television networks.

Methods and apparatus to determine audience duplication in cross-media campaigns

Controlled release oral solid dosage form for the reduction of serum cholesterol levels in humans include a drug comprising an alkyl ester of hydroxy substituted naphthalenes (e.g., lovastatin) and a controlled release carrier, such that the dosage form provides a mean time to maximum plasma concentration (T) of the drug which occurs at about 10 to about 32 hours after oral administration on a once-a-day basis to human patients. The dosage form provides a therapeutically effective reduction in serum cholesterol levels. Methods of reducing serum cholesterol levels in humans are also disclosed.

HMG-CoA reductase inhibitor extended release formulation

Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Methods and formulations for making pharmaceutical compositions containing bupropion

The present invention relates to an oral particle composition as an ingredient in an extended-release tablet formulation, comprising a core and a coat, wherein the coat is acid-soluble.

Oral particle compositions containing a core and an acid-soluble coat

The present invention relates to an oral tablet composition for pharmaceutical use, comprising (1) a particle comprising an amorphous structure and a submicron domain and (2) a pharmaceutically acceptable carrier, wherein the composition is optionally coated.

Oral solid composition

Growing community of inventors

Commerce, CA, United States of America

David N Wong